MeiraGTx Holdings plc — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. The filing is an annual report, not a standalone fourth-quarter report; quarterly Q4 results are not separately presented in the supplied text. The company is a clinical-stage gene therapy business and had no product revenue.
Business context and reporting period
MeiraGTx develops gene therapies, with clinical programs in inherited retinal diseases, radiation-induced xerostomia and Parkinson’s disease, alongside preclinical and research programs. It operates a UK cGMP manufacturing facility. The company completed its IPO in June 2018 and acquired Vector Neurosciences in October 2018, adding the AAV-GAD Parkinson’s program.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Product revenue | None | None |
| Operating expenses | $78.1 million | $31.7 million |
| Operating loss | $78.1 million | $31.7 million |
| Net loss | $82.9 million | $31.0 million |
| Net loss per ordinary share | $4.47 | $3.72 |
| Cash used in operating activities | $58.9 million | $18.1 million |
| Cash used in investing activities | $11.3 million | $10.5 million |
| Cash provided by financing activities | $130.0 million | $19.3 million |
At December 31, 2018, cash and cash equivalents were $68.1 million, compared with $8.5 million a year earlier. Total assets were $96.9 million; current assets were $74.7 million and current liabilities $15.5 million. Total liabilities were $15.8 million. The company reported no debt outstanding at year-end other than lease obligations; its $1.4 million note payable had been repaid in 2018. No revenue-based margin is meaningful because the company had no product sales.
Research and development expense rose to $33.6 million from $22.4 million, while general and administrative expense increased to $44.5 million from $9.3 million. Management attributed the G&A increase mainly to payroll and share-based compensation; total share-based compensation was $17.9 million, versus $3.0 million. The 2018 net loss also included a $3.8 million foreign-currency loss, compared with a $1.7 million gain in 2017. The independent auditor issued an unqualified opinion on the financial statements.
Material changes and developments
- Net loss widened by $51.8 million year over year as operating expenses increased substantially, particularly G&A and R&D.
- Cash increased following financing activity, including the IPO, preferred-share financing and warrant exercises. The company spent $11.3 million on investing activities, primarily property and equipment for its manufacturing facility.
- In December 2018, MeiraGTx paid approximately $6.6 million for a long leasehold interest in the facility site; it reported no facility rent due under the resulting 108-year remaining term.
- After year-end, the company entered a Janssen collaboration for selected retinal-disease programs. The disclosed terms include a $100 million upfront payment, research funding, potential milestones of up to $340 million and untiered 20% royalties on sales of the specified programs. Janssen is to fund their clinical and commercialization costs; MeiraGTx is to manufacture commercial supply.
- After year-end, MeiraGTx also completed an approximately $80 million private placement, with net proceeds of approximately $77.4 million. Management estimated that year-end cash plus these proceeds and the Janssen upfront payment would fund operations and capital needs into 2022; this is an estimate based on assumptions, not a guarantee.
Outlook, commentary and key risks
Management expects R&D and G&A spending to rise as trials, manufacturing and public-company activities expand. The company has no approved products and expects continuing losses; it may need additional capital if development costs or timelines exceed assumptions. Management cited a projected cash runway into 2022 after the specified post-year-end funding.
Clinical milestones described as expectations included 2019 data updates for several eye programs, initiation of a CNGA3 Phase 1/2 trial, and further development of the xerostomia and ALS programs. These are forward-looking plans, not reported outcomes. AAV-GAD’s future clinical and regulatory path had not yet been determined through formal regulatory-agency meetings.
Material risks include clinical failure or delays, gene-therapy safety and long-term effects, manufacturing and supply constraints, dependence on collaborators and licensed intellectual property, competition, future financing and shareholder dilution, reimbursement uncertainty, and foreign-exchange exposure. The filing reports no material legal proceedings. Disclosure controls were assessed as effective at the reasonable-assurance level; management’s internal-control report and auditor attestation were not included under the applicable transition exemptions.
Investor facts to verify
- Confirm receipt and timing of the Janssen upfront payment and research funding, and review the collaboration’s scope, option rights, milestones, royalties and manufacturing obligations.
- Track cash burn against management’s runway estimate, including spending required for clinical trials, manufacturing and capital needs.
- Review final clinical-trial safety and efficacy data and regulatory feedback; early or interim observations do not establish approval or commercial benefit.
- Assess the drivers and persistence of elevated G&A and share-based compensation, along with dilution from the 2019 placement and outstanding equity awards.
- Verify the effect of foreign-exchange movements, lease commitments and any future financing needs on liquidity.